Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last41 to 60 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| PCV13-vaccinated Participants vs Unvaccinated Participants: VE for First Event of ACP at 0-3 Years of Follow-up | 4,543 of 72,303 27,984 of 320,959 | -2.4 points -2.6 to -2.2 | 393,262 | NCT05794191 A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV |
| Aims 1, 2B, and 3 Groups vs Aim 2A Group: deaths from any cause | 22,208 of 386,276 0 of 25 | 5.7 points -7.6 to 5.8 | 386,301 | NCT05214573 Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk |
| Aims 1, 2B, and 3 Groups vs Aim 2A Group: serious adverse events | 40,642 of 386,276 0 of 25 | 10.5 points -2.8 to 10.6 | 386,301 | NCT05214573 Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk |
| Rivaroxaban vs Apixaban: deaths from any cause | 1,958 of 176,990 1,840 of 176,990 | 0.1 points -0.0 to 0.1 | 353,980 | NCT05256797 Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data |
| Arm 1: Routine Care (Mupirocin/CHG) vs Arm 2: Iodophor/CHG Decolonization: Number of Participants With ICU Attributable MRSA Clinical Cultures | 1,377 of 168,301 1,682 of 185,022 | -0.1 points -0.2 to -0.0 | 353,323 | NCT03140423 Mupirocin-Iodophor ICU Decolonization Swap Out Trial |
| Arm 1: Routine Care (Mupirocin/CHG) vs Arm 2: Iodophor/CHG Decolonization: Number of Participants With ICU-attributable Staphylococcus Aureus Clinical Cultures | 2,708 of 168,301 3,563 of 185,022 | -0.3 points -0.4 to -0.2 | 353,323 | NCT03140423 Mupirocin-Iodophor ICU Decolonization Swap Out Trial |
| Arm 1: Routine Care (Mupirocin/CHG) vs Arm 2: Iodophor/CHG Decolonization: Number of Participants With ICU-attributable Bloodstream Infections | 1,766 of 168,301 1,956 of 185,022 | -0.0 points -0.1 to 0.1 | 353,323 | NCT03140423 Mupirocin-Iodophor ICU Decolonization Swap Out Trial |
| Cases vs Controls: Number of Participants BMI <30 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person | 1,398 of 92,915 3,188 of 249,186 | 0.2 points 0.1 to 0.3 | 342,101 | NCT04969653 The Incidence of Venous Thromboembolism in Atopic Dermatitis |
| Intervention Arm vs Usual Care Arm: Receipt of Flu Vaccine | 76,295 of 148,291 96,561 of 190,427 | 0.7 points 0.4 to 1.1 | 338,718 | NCT05027464 Developing and Testing a COVID-19 Vaccination Acceptance Intervention |
| Intervention Arm vs Usual Care Arm: Receipt of Any Dose COVID-19 Vaccination | 57,621 of 148,291 65,407 of 190,427 | 4.5 points 4.2 to 4.8 | 338,718 | NCT05027464 Developing and Testing a COVID-19 Vaccination Acceptance Intervention |
| SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause | 1,371 of 163,812 2,524 of 163,812 | -0.7 points -0.8 to -0.6 | 327,624 | NCT03817463 A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes |
| Intervention Health Facility Participants vs Control Health Facility Participants: deaths from any cause | 3,917 of 159,587 3,677 of 154,684 | 0.1 points -0.0 to 0.2 | 314,271 | NCT02148952 BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program |
| Cases vs Controls: Number of Male Participants With Diagnosis of Risk of Venous Thromboembolism After the Start of Follow-up for Each Person | 1,070 of 61,882 3,170 of 247,459 | 0.4 points 0.3 to 0.6 | 309,341 | NCT04969653 The Incidence of Venous Thromboembolism in Atopic Dermatitis |
| Preoperative Geriatric Consult or Assessment vs No Preoperative Geriatric Consult or Assessment: 30-day Hospital Readmission | 643 of 7,352 20,656 of 259,147 | 0.8 points 0.1 to 1.5 | 266,499 | NCT02975375 The Impact of Perioperative Geriatric Care on Outcomes After Elective Noncardiac Surgery |
| Preoperative Geriatric Consult or Assessment vs No Preoperative Geriatric Consult or Assessment: deaths from any cause | 103 of 7,352 6,172 of 259,147 | -1.0 points -1.2 to -0.7 | 266,499 | NCT02975375 The Impact of Perioperative Geriatric Care on Outcomes After Elective Noncardiac Surgery |
| Preoperative Geriatric Consult or Assessment vs No Preoperative Geriatric Consult or Assessment: Non-independent Discharge Location | 5,264 of 7,352 145,822 of 259,147 | 15.3 points 14.3 to 16.4 | 266,499 | NCT02975375 The Impact of Perioperative Geriatric Care on Outcomes After Elective Noncardiac Surgery |
| Preoperative Geriatric Consult or Assessment vs No Preoperative Geriatric Consult or Assessment: Patient Safety Event | 1,129 of 7,352 50,256 of 259,147 | -4.0 points -4.9 to -3.2 | 266,499 | NCT02975375 The Impact of Perioperative Geriatric Care on Outcomes After Elective Noncardiac Surgery |
| Preoperative Geriatric Consult or Assessment vs No Preoperative Geriatric Consult or Assessment: Number of Participants With All-Cause Mortality at 90-days | 103 of 7,352 6,172 of 259,147 | -1.0 points -1.2 to -0.7 | 266,499 | NCT02975375 The Impact of Perioperative Geriatric Care on Outcomes After Elective Noncardiac Surgery |
| Polypharmacy vs No Polypharmacy: Institutional Discharge | 34,128 of 146,029 23,098 of 120,470 | 4.2 points 3.9 to 4.5 | 266,499 | NCT03133182 Polypharmacy and Outcomes After Elective Noncardiac Surgery |
| Polypharmacy vs No Polypharmacy: Hospital Readmission | 13,202 of 146,029 8,097 of 120,470 | 2.3 points 2.1 to 2.5 | 266,499 | NCT03133182 Polypharmacy and Outcomes After Elective Noncardiac Surgery |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=3
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT05794191-8181103b",
"title": "PCV13-vaccinated Participants vs Unvaccinated Participants: VE for First Event of ACP at 0-3 Years of Follow-up",
"summary": "4543 of 72303 against 27984 of 320959; risk difference -2.4 points, 95% interval -2.6 to -2.2; NCT05794191, A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV",
"record": "/library/comparisons/NCT05794191-8181103b",
"nct_id": "NCT05794191",
"kind": "outcome",
"participants": 393262,
"risk_difference": {
"value": -0.024355905493700133,
"lower": -0.026358286689202724,
"upper": -0.022317628326311127
},
"group_1": "4,543 of 72,303",
"group_2": "27,984 of 320,959",
"difference": "-2.4 points",
"interval": "-2.6 to -2.2",
"trial_title": "A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV"
},
{
"id": "NCT05214573-deaths",
"title": "Aims 1, 2B, and 3 Groups vs Aim 2A Group: deaths from any cause",
"summary": "22208 of 386276 against 0 of 25; risk difference 5.7 points, 95% interval -7.6 to 5.8; NCT05214573, Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk",
"record": "/library/comparisons/NCT05214573-deaths",
"nct_id": "NCT05214573",
"kind": "deaths",
"participants": 386301,
"risk_difference": {
"value": 0.05749257007942508,
"lower": -0.0757016796695989,
"upper": 0.058231067159930726
},
"group_1": "22,208 of 386,276",
"group_2": "0 of 25",
"difference": "5.7 points",
"interval": "-7.6 to 5.8",
"trial_title": "Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=4",
"request_id": "NO8379cTWC8NACvl"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant